According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) released its 2022 annual report. The company's revenue was 885 million yuan, a decrease of 27.80% over the previous year. The net loss attributable to shareholders of listed companies was 687.091 million yuan, a year-on-year decrease of 31.65%. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was $115 million, a year-on-year decrease of 16.43%. The basic loss per share was $0.0651.

The loss in performance in 2022 was mainly affected by a combination of factors such as the national collection policy and continued maintenance of large R&D investment. Influenced by the national collection policy, the sales volume and sales unit price of the company's key product, esomeprazole enteric capsules, declined further, and sales revenue and profits declined accordingly; due to logistics stoppages in some regions during the reporting period, demand for hospitalization declined, which also had a certain impact on the delivery and sales of the company's related products.